Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 41 Total
SLNG - Stabilis Solutions Inc - Stock Price Chart
TickerSLNG [NASD]
CompanyStabilis Solutions Inc
CountryUSA
IndustryOil & Gas Integrated
Market Cap73.62MEPS (ttm)0.03
P/E148.31EPS this Y3300.00%
Forward P/E11.31EPS next Y2.94%
PEG-EPS past 5Y-
P/S1.11EPS next 5Y-
P/B1.16EPS Q/Q35.21%
Dividend-Sales Q/Q-26.35%
Insider Own88.41%Inst Own3.67%
Insider Trans0.03%Inst Trans20.27%
Short Float0.19%EarningsMay 07/a
Analyst Recom1.00Target Price9.00
Avg Volume4.46K52W Range3.85 - 6.40
Stabilis Solutions, Inc. engages in the provision of small-scale liquefied natural gas production, distribution, and fueling services to multiple end markets. It operates through the following segments: LNG and Power Delivery. The LNG segment supplies LNG to the industrial, midstream, and oilfield sectors in North America and provides turnkey fuel solutions to help users of propane, diesel and other crude-based fuel products convert to LNG. The Power Delivery segment provides power delivery solutions to the global energy industry through its subsidiary in Brazil and joint venture in China. The company was founded on October 21, 1996 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Puhala Andrew LewisChief Financial OfficerJun 07 '24Buy4.151,0004,15033,618Jun 07 04:03 PM
Puhala Andrew LewisChief Financial OfficerMay 22 '24Buy3.991,1384,54132,618May 23 06:54 PM
Mitchell Peter C.DirectorMay 15 '24Buy4.143,56414,75325,000May 17 02:00 PM
KUNTZ EDWARD LDirectorNov 13 '23Buy4.915,00024,55058,172Nov 14 08:45 AM
Ballard Westervelt T. JRPresident and CEOAug 23 '23Option Exercise0.00125,0000432,916Aug 25 04:46 PM
CVR - Chicago Rivet & Machine Co. - Stock Price Chart
TickerCVR [AMEX]
CompanyChicago Rivet & Machine Co.
CountryUSA
IndustryTools & Accessories
Market Cap15.04MEPS (ttm)-4.67
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.49EPS next 5Y-
P/B0.59EPS Q/Q-19.70%
Dividend2.58%Sales Q/Q-10.04%
Insider Own23.60%Inst Own18.72%
Insider Trans0.00%Inst Trans-1.37%
Short Float0.58%Earnings-
Analyst Recom-Target Price-
Avg Volume1.96K52W Range14.73 - 28.00
Chicago Rivet & Machine Co. engages in the manufacturing and sale of rivets and specialty cold formed parts, as well as automatic rivet setting equipment and automated assembly systems. It operates through the following segments: Fasteners and Assembly Equipment. The Fasteners segment includes rivets, cold-formed fasteners, and parts and screw machine products. The Assembly Equipment segment consists of automatic rivet setting machines and parts and tools for such machines. The company was founded in 1920 and is headquartered in Naperville, IL.
MNOV - Medicinova Inc - Stock Price Chart
TickerMNOV [NASD]
CompanyMedicinova Inc
CountryUSA
IndustryBiotechnology
Market Cap64.26MEPS (ttm)-0.17
P/E-EPS this Y-35.29%
Forward P/E-EPS next Y-4.35%
PEG-EPS past 5Y13.30%
P/S64.26EPS next 5Y20.00%
P/B1.07EPS Q/Q5.55%
Dividend-Sales Q/Q-
Insider Own5.24%Inst Own18.55%
Insider Trans0.00%Inst Trans-0.93%
Short Float0.29%EarningsMay 10/b
Analyst Recom1.00Target Price16.50
Avg Volume30.09K52W Range1.26 - 2.66
Jun-05-24 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer (GlobeNewswire)
Jun-03-24 06:00AM MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire) +8.09%
May-28-24 06:00AM MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions (GlobeNewswire)
May-20-24 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer (GlobeNewswire)
May-14-24 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
May-10-24 08:52AM MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 (InvestorPlace)
May-09-24 07:45PM MediciNova: Q1 Earnings Snapshot (Associated Press Finance) +8.15%
May-07-24 06:00AM MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) (GlobeNewswire)
Apr-02-24 07:00PM MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) (GlobeNewswire)
Mar-26-24 07:00PM MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan (GlobeNewswire) +8.09%
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.
USGO - U.S. GoldMining Inc - Stock Price Chart
TickerUSGO [NASD]
CompanyU.S. GoldMining Inc
CountryCanada
IndustryOther Industrial Metals & Mining
Market Cap74.40MEPS (ttm)-0.76
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B6.69EPS Q/Q-6.45%
Dividend-Sales Q/Q-
Insider Own89.07%Inst Own4.21%
Insider Trans0.00%Inst Trans-
Short Float0.07%Earnings-
Analyst Recom1.00Target Price23.50
Avg Volume9.59K52W Range4.91 - 13.98
U.S. GoldMining, Inc. operates as a gold and copper exploration company. It focuses on unlocking the substantial value of the Whistler gold-copper project. The company was founded on June 30, 2015 and is headquartered in Vancouver, Canada.
NKGN - NKGen Biotech Inc - Stock Price Chart
TickerNKGN [NASD]
CompanyNKGen Biotech Inc
CountryUSA
IndustryBiotechnology
Market Cap29.62MEPS (ttm)-4.37
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-1486.44%
Dividend-Sales Q/Q-
Insider Own52.88%Inst Own9.71%
Insider Trans0.00%Inst Trans12.77%
Short Float5.12%Earnings-
Analyst Recom-Target Price-
Avg Volume1.93M52W Range0.78 - 12.88
Jun-12-24 01:05PM NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -8.51%
Jun-03-24 08:05AM NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -6.59%
May-23-24 05:05PM NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -23.66%
May-21-24 09:53AM NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024 (InvestorPlace)
May-20-24 11:41AM NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today (InvestorPlace) +52.68%
08:05AM NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease (GlobeNewswire)
May-16-24 08:05AM NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition (GlobeNewswire)
Apr-29-24 08:00AM NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease (GlobeNewswire)
Apr-25-24 04:05PM NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) +15.79% -18.69%
Apr-24-24 04:45PM NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.57%
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Song Paul Y.Chief Executive OfficerDec 07 '23Buy3.2976250171,121Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 06 '23Buy3.3275250171,045Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 05 '23Buy3.33105350170,969Dec 05 03:51 PM
Graf James AInterim CFODec 04 '23Buy3.194501,436693Dec 05 03:50 PM
Song Paul Y.Chief Executive OfficerDec 04 '23Buy3.07163500170,864Dec 05 03:51 PM
ARGX - Argen X SE ADR - Stock Price Chart
TickerARGX [NASD]
CompanyArgen X SE ADR
CountryNetherlands
IndustryBiotechnology
Market Cap22.46BEPS (ttm)-5.17
P/E-EPS this Y50.10%
Forward P/E125.48EPS next Y216.99%
PEG-EPS past 5Y-17.05%
P/S18.29EPS next 5Y64.60%
P/B5.46EPS Q/Q10.02%
Dividend-Sales Q/Q82.26%
Insider Own0.71%Inst Own56.75%
Insider Trans0.00%Inst Trans-7.14%
Short Float2.18%EarningsMay 09/b
Analyst Recom1.61Target Price467.52
Avg Volume263.99K52W Range327.73 - 550.76
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
ALB - Albemarle Corp. - Stock Price Chart
TickerALB [NYSE, S&P 500]
CompanyAlbemarle Corp.
CountryUSA
IndustrySpecialty Chemicals
Market Cap11.70BEPS (ttm)2.75
P/E36.24EPS this Y-85.50%
Forward P/E14.03EPS next Y119.94%
PEG2.41EPS past 5Y16.09%
P/S1.39EPS next 5Y15.02%
P/B1.26EPS Q/Q-100.74%
Dividend1.60%Sales Q/Q-47.26%
Insider Own0.43%Inst Own95.40%
Insider Trans-0.46%Inst Trans1.71%
Short Float13.62%EarningsMay 01/a
Analyst Recom2.10Target Price145.22
Avg Volume2.51M52W Range98.95 - 247.44
Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, Ketjen, and All Other. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The All Other segment refers only to the FCS business that did not fit into any of the company's core businesses. The company was founded in 1993 and is headquartered in Charlotte, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mummert Mark RichardSVP, Capital ProjectsMay 14 '24Sale135.53843114,2506,802May 15 05:00 PM
Barichivich John Clarence IIIVP, Controller & CAOMay 13 '24Sale132.171,475194,9514,743May 14 04:39 PM
Johnson Netha N.President, SpecialtiesFeb 28 '24Option Exercise0.001,680032,163Mar 01 04:54 PM
Norris EricPresident, Energy StorageFeb 28 '24Option Exercise0.001,680035,585Mar 01 04:55 PM
Barichivich John Clarence IIIVP, Controller & CAOFeb 28 '24Option Exercise0.0053506,375Mar 01 04:56 PM
PRQR - ProQR Therapeutics N.V - Stock Price Chart
TickerPRQR [NASD]
CompanyProQR Therapeutics N.V
CountryNetherlands
IndustryBiotechnology
Market Cap135.96MEPS (ttm)-0.36
P/E-EPS this Y-24.68%
Forward P/E-EPS next Y-14.57%
PEG-EPS past 5Y21.74%
P/S12.18EPS next 5Y-
P/B3.62EPS Q/Q14.01%
Dividend-Sales Q/Q587.25%
Insider Own35.42%Inst Own22.22%
Insider Trans0.00%Inst Trans-2.73%
Short Float0.46%EarningsMay 09/b
Analyst Recom1.43Target Price4.24
Avg Volume127.74K52W Range1.11 - 3.29
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
AEHL - Antelope Enterprise Holdings Ltd - Stock Price Chart
TickerAEHL [NASD]
CompanyAntelope Enterprise Holdings Ltd
CountryChina
IndustryBuilding Products & Equipment
Market Cap17.82MEPS (ttm)-3.79
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y57.87%
P/S0.25EPS next 5Y-
P/B0.48EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own54.30%Inst Own0.29%
Insider Trans0.00%Inst Trans161.85%
Short Float3.11%EarningsMay 07/b
Analyst Recom-Target Price-
Avg Volume272.36K52W Range1.22 - 9.40
Antelope Enterprise Holdings Ltd. engages in the manufacture and sale of ceramics tiles. Its products operates through the Hengda, the Hengdeli or HDL brand, TOERTO, WULIQIAO, and Pottery Capital of Tang Dynasty brands. It offers porcelain, glazed, glazed porcelain, rustic, and polished glazed tiles. The company was founded by Jia Dong Huan on September 30, 1993 and is headquartered in Chengdu, China.
FBIZ - First Business Financial Services Inc - Stock Price Chart
TickerFBIZ [NASD, RUT]
CompanyFirst Business Financial Services Inc
CountryUSA
IndustryBanks - Regional
Market Cap282.27MEPS (ttm)4.36
P/E7.80EPS this Y4.53%
Forward P/E6.57EPS next Y14.49%
PEG0.98EPS past 5Y18.43%
P/S1.18EPS next 5Y8.00%
P/B0.99EPS Q/Q-0.98%
Dividend2.94%Sales Q/Q23.91%
Insider Own12.64%Inst Own57.40%
Insider Trans-0.09%Inst Trans-1.68%
Short Float0.26%EarningsApr 25/a
Analyst Recom1.60Target Price42.80
Avg Volume11.86K52W Range28.35 - 41.03
First Business Financial Services, Inc. operates as a bank holding company, which engages in the provision of commercial banking services. It offers treasury and investment management, commercial lending, equipment finance, retirement plans, trust and estate administration, private banking and asset-based lending. The company was founded in 1986 and is headquartered in Madison, WI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Crampton Kevin DChief Accounting OfficerMay 21 '24Buy34.151545,2601,257May 23 04:32 PM
Lorenz William KentDirectorMay 13 '24Sale34.511,34546,4169,836May 14 04:37 PM
Lorenz William KentDirectorMay 10 '24Sale35.00802,80011,181May 14 04:37 PM
Sanders Carol PDirectorMay 01 '24Buy34.401756,01910,218May 03 04:13 PM
Sanders Carol PDirectorJan 30 '24Buy38.371565,98610,043Jan 31 04:49 PM
12345